Roche’s live audio webcast and conference call from ESMO IO 2017

On-demand MP3
The on-demand is available here 

Agenda

• IMpower150: Phase 3 results of carboplatin + paclitaxel +/- Avastin, with or without Tecentriq in 1L non-squamous metastatic NSCLC
  Alan Sandler, M.D., Global Development Team Leader Tecentriq Lung
• Tecentriq program overview: Focusing on novel combination approaches
  Cathi Ahearn, Global Product Strategy Tecentriq